source
- Summit Therapeutics' Akeso cuts death risk by 34% in Chinese lung cancer trial presented at ASCO 2026Summit Therapeutics reported at the ASCO 2026 meeting that its experimental drug Akeso lowered the risk of death by 34% for previously untreated lung cancer patients in China when compared with the…
- Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survivalA trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…